Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04607733 · ClinicalTrials.gov registry record · Phase 1
A Study of Mirikizumab in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
NCT04607733: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT04607733 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 240 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (300% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04607733, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare the amount of mirikizumab that gets into the blood stream and how long it takes the body to get rid of it, when given as a solution formulation via manual prefilled syringe or autoinjector. The information about any adverse effects experienced will be collected and the tolerability of mirikizumab will also be evaluated. Screening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be about 17 weeks, including screening.
Primary Outcome
PK: Cmax of Mirikizumab
Interventions
- DRUG Mirikizumab Prefilled Syringe
- DRUG Mirikizumab Autoinjector
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2020-11-02 |
| Est. Completion | 2021-05-17 |
| Phase | Phase 1 |
What the finished NCT04607733 record still lists
NCT04607733 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (300% higher).
The record links to 0 conditions, and to 2 interventions - of which Mirikizumab Prefilled Syringe is the first listed.
NCT04607733 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04607733 about?
NCT04607733 is a clinical study titled "A Study of Mirikizumab in Healthy Participants". The main purpose of this study is to compare the amount of mirikizumab that gets into the blood stream and how long it takes the body to get rid of it, when given as a solution formulation via manual prefilled syringe or autoinjector. The information about any adverse effects experienced will be col...
What is the current status of trial NCT04607733?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2020-11-02. Estimated completion is 2021-05-17.
What interventions are being tested in trial NCT04607733?
The interventions under investigation include: Mirikizumab Prefilled Syringe (DRUG), Mirikizumab Autoinjector (DRUG).
Who is sponsoring clinical trial NCT04607733?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04607733's enrollment target sits among peer trials
240 197th of 2000 higher than 1,789 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI